Drugs / ENBEZOTINIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04161391 | Dec 2019 → May 2023 | medullary thyroid gland carcinoma, metastatic neoplasm, non-small cell lung carcinoma | Turning Point Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENBEZOTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095062 ↗ |
| Known as | TPX-0046 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04161391 ↗ |
| Action | Inhibit | “RET/SRC inhibitor” NCT04161391 ↗ |
| Modality | Small molecule | — CHEMBL5095062 ↗ |
| Route | Oral | “Oral TPX-0046 capsules” NCT04161391 ↗ |
| Target | RET | “RET/SRC inhibitor” NCT04161391 ↗ |
| Target | SRC | “RET/SRC inhibitor” NCT04161391 ↗ |